Back

Gaps between guidelines and everyday clinical practice in the treatment of heart failure patients with reduced ejection fraction (HFrEF): we still have much to learn

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Marko Galich

General Hospital Slavonski Brod, Slavonski Brod (Croatia)

8 More presentations in this session

Presentation thumbnail
Discussant - Pharmacotherapy for heart failure (1)
Presentation thumbnail
Finerenone in patients with heart failure and diabetic kidney disease: comparison of mineralocorticoid receptor antagonists. FINARM study
Mr E. Boada Lincango (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
A novel, Pillar-GDMT score for prediction of all-cause mortality in patients with heart failure with reduced ejection fraction requiring heart failure hospitalisation
Doctor B. Muk (Budapest, HU)
Abstract
Presentation thumbnail
SGLT2i and ARNI improve long-term heart failure outcomes: a multi-state model analysis from a real-world southeast asian cohort
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF
Doctor A. Urbinati (New York, US)
Abstract Slides

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Challenges in heart failure ESC Guidelines implementation - insights from a real world registry.
thumbnail
Congress Session
Rapid optimisation of evidence-based treatment for heart failure with reduced ejection fraction: how to do it
thumbnail
Congress Presentation
Analysis of guideline-directed medical therapy in patients with reduced ejection fraction undergoing pulsed field ablation for atrial fibrillation: a multicentre study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources